natgillin/translations-raw huggingface dataset:
Det hæmmer ikke CYP3A4 in vivo. 
It is not an inhibitor of CYP3A4 in vivo.
Det anbefalede dosisregime er en filmovertrukket Symtuza-tablet én gang dagligt, der tages sammen med mad. 
ART-naïve patients The recommended dose regimen is one film-coated tablet of Symtuza once daily taken with food.
Dyrestudier har ikke påvist nogen direkte skadelige virkninger med hensyn til drægtighed, embryo-/fosterudvikling, fødsel eller postnatal udvikling (se pkt. 
Studies in animals do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Patienterne var virologisk supprimerede i mindst 2 måneder og havde højst én gang en forhøjelse af den virale belastning på mere end 50 hiv-1 RNA-kopier/ml i løbet af et år forud for rekruttering. 
Patients were virologically suppressed for at least 2 months and no more than once had a viral load elevation above 50 HIV-1 RNA copies/mL during the year prior to enrollment.
Uge 48 D/C + F/TDF 
Week 48 D/C + F/TDF
Tretten procent af emtricitabindosen blev genfundet i urinen som tre metabolitter. 
Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites.
Emtricitabins biotransformation omfatter oxidation af thioldelen, hvorved der dannes 3'-sulfoxiddiastereomere (ca. 9 % af dosen), og konjugering med glukuronsyre, hvorved der dannes 2'-O-glukuronid (ca. 4 % af dosen). 
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).
Da der er en lavere eksponering for tenofovir hos rotter og mus efter administration af tenofoviralafenamid sammenlignet med tenofovirdisoproxil, blev karcinogenicitetsstudier og et peri-postnatalt studie af rotter kun udført med tenofovirdisoproxil. 
Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil.
Patienterne var på et stabilt ARV-regime (i mindst 6 måneder) bestående af en boostet proteasehæmmer [enten darunavir en gang dagligt eller atazanavir (begge boostet med ritonavir eller cobicistat), eller lopinavir med ritonavir] kombineret med emtricitabin og TDF. 
Patients were on a stable ARV regimen (for at least 6 months), consisting of a boosted protease inhibitor [either darunavir once daily or atazanavir (both boosted with ritonavir or cobicistat), or lopinavir with ritonavir] combined with emtricitabine and TDF.
Til behandling af pulmonal arteriel hypertension Sildenafil Tadalafil 
For the treatment of pulmonary arterial hypertension Sildenafil Tadalafil
Symtuza reducerer hiv-1 i kroppen, og dette forbedrer dit immunforsvar (kroppens naturlige forsvarssystem) og nedsætter risikoen for at udvikle sygdomme, der er forbundet med hiv-infektion. 
Symtuza reduces HIV-1 in your body and this will improve your immune system (your body's natural defences) and reduce the risk of developing illnesses linked to HIV infection but Symtuza is not a cure for HIV infection.
Systemisk dexamethason skal anvendes med forsigtighed ved kombination med Symtuza. 
Systemic dexamethasone should be used with caution when combined with Symtuza.
Nedsat følsomhed over for emtricitabin er associeret med 184V/I-mutationer i hiv-1 RT. 
Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.
For emtricitabin var Cmax 1,26 gange højere i fastende tilstand, mens AUC var sammenlignelig i ikke-fastende og fastende tilstand. 
For emtricitabine, the Cmax was 1.26-fold higher in a fasted condition, while the AUC was comparable in fed and fasted condition.
Cobicistat har ingen påviselig antiviral aktivitet over for hiv-1 og antagoniserer ikke darunavirs, emtricitabins eller tenofovirs antivirale virkning. 
Cobicistat has no detectable antiviral activity against HIV-1 and does not antagonise the antiviral effect of darunavir, emtricitabine, or tenofovir.
Cobicistat er 97-98 % bundet til humane plasmaproteiner, og forholdet mellem gennemsnitlig lægemiddelkoncentration i plasma og blod var cirka 2. 
Cobicistat is 97% to 98% bound to human plasma proteins and the mean plasma to blood-drug concentration ratio was approximately 2.
Øget overvågning af ASAT/ALAT skal overvejes hos patienter med underliggende kronisk hepatitis eller cirrose og hos patienter med forhøjede aminotransferaser før behandlingen - specielt i de første måneder af Symtuza-behandling. 
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of Symtuza treatment.
Tenofovir elimineres fra kroppen af nyrerne, både ved glomerulær filtration og aktiv tubulær sekretion. 
Tenofovir is eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion.
Det er vigtigt ikke at holde op med at tage Symtuza uden først at tale med lægen. 
It is important not to stop taking Symtuza without talking to your doctor first.
• en reaktion kaldet DRESS [et alvorligt udslæt, der kan være ledsaget af feber, træthed, hævelser af ansigtet eller lymfekirtler, øgning i antallet af eosinofile celler (en type hvide blodlegemer) samt påvirkning af lever, nyrer eller lunger]. 
• a reaction called DRESS [severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung].
C]-darunavir med ritonavir i en dosis på 400/100 mg kunne ca. 79,5 % og 13,9 % af det administrerede [ 
C]-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of [
Du må ikke holde op med at tage Symtuza uden først at tale med din læge 
Do not stop taking Symtuza without talking to your doctor first
Darunavir og cobicistat metaboliseres af CYP3A. 
Darunavir and cobicistat are metabolised by CYP3A.
INHALEREDE BETA-AGONISTER Salmeterol 
INHALED BETA AGONISTS Salmeterol
Ved uge 48 var ændringerne fra baseline mindre med D/C/F/TAF end med D/C+F/TDF. 
At Week 48 changes from baseline were smaller with D/C/F/TAF than D/C+F/TDF.
Din læge skal tage nogle blodprøver, før du starter på Symtuza. 
Your doctor should do blood tests before you start Symtuza.
Fordelingen af tenofoviralafenamid i kroppen kan påvirkes af aktiviteten af OATP1B1 og OATP1B3. 
The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.
C]-darunavir med ritonavir viste, at ca. 7,7 % af den administrerede darunavirdosis udskilles uomdannet i urinen. 
C]-darunavir with ritonavir showed that approximately 7.7% of the administered dose of darunavir is excreted in the urine unchanged.
Symtuza kan nedsætte virkningen af disse. 
Symtuza might reduce its effectiveness.
Middelstigning fra baseline ved Uge 48 D/C/F/TAF 
Median Increase From Baseline at Week 48 D/C/F/TAF
Patienter co-inficeret med hepatitis B- og/eller hepatitis C-virus Der foreligger kun begrænsede oplysninger om brugen af komponenterne i Symtuza hos patienter, der er co-inficeret med hepatitis B og/eller hepatitis C-virus. 
Patients co-infected with hepatitis B and/or hepatitis C virus Limited information is available on the use of Symtuza components in patients co-infected with hepatitis B and/or C virus.
Disse resultater blev tilskrevet de umodne leverenzymer og den umodne blod-hjernebarriere. 
These findings were attributed to the immaturity of the liver enzymes and of the blood brain barrier.
Tenofoviralafenamid er virksomt over for hepatitis B-virus (HBV). 
Tenofovir alafenamide is active against hepatitis B virus (HBV).
Med hensyn til monitorering af lipider og glucose i blodet henvises der til eksisterende behandlingsguidelines for hiv. 
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines.
Dosisjustering af buprenorphin er muligvis ikke nødvendig ved co-administration med Symtuza, men omhyggelig klinisk monitorering for tegn på opioidtoksicitet anbefales. 
Dose adjustment for buprenorphine may not be necessary when co-administered with Symtuza, but a careful clinical monitoring for signs of opiate toxicity is recommended.
PHOSPHODIESTERASE TYPE 5 (PDE-5)-HÆMMERE Til behandling af erektil dysfunktion Sildenafil Tadalafil Vardenafil 
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS For the treatment of erectile dysfunction Sildenafil Tadalafil Vardenafil
Autoimmune lidelser kan opstå, mange måneder efter påbegyndt behandling. 
Autoimmune disorders may occur many months after the start of treatment.
Symtuza-tabletterne fås i pakninger med én beholder eller tre beholdere pr. karton. 
The Symtuza tablets are available in packs containing one bottle or three bottles per carton.
I fase 3-studiet med Symtuza af behandlingsnaive patienter opstod der stigninger i serumkreatinin og fald i eGFRCG ved den første evaluering i behandling (uge 2) og forblev stabile over 96 uger. 
In the Phase 3 trial of Symtuza in treatment-naïve patients, increases in serum creatinine and decreases in eGFRCG occurred at the first on-treatment assessment (Week 2) and remained stable through 96 weeks.
Omend ætiologien anses for at være multifaktoriel (herunder kortikosteroidbehandling, alkoholforbrug, alvorlig immunsuppression, højt BMI), er der rapporteret tilfælde af osteonekrose, især hos patienter med fremskreden hiv-sygdom og/eller langvarig eksponering for antiretroviral kombinationsbehandling (CART). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART).
Både på grund af risikoen for hiv-transmission og på grund af risikoen for bivirkninger hos det ammede spædbarn skal moderen instrueres i ikke at amme, hvis hun behandles med Symtuza. 
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed if they are receiving Symtuza.
Dosisreduktion eller afbrydelse af behandlingen med colchicin anbefales hos patienter med normal nyre- og leverfunktion, hvis behandling med Symtuza er nødvendig. 
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Symtuza is required.
Udslættet var for det meste let til moderat og opstod ofte inden for de første fire ugers behandling og fortog sig under den fortsatte behandling (se pkt. 
Rash was mostly mild to moderate, often occurring within the first four weeks of treatment and resolving with continued dosing (see section 4.4).
Det er påvist, at cobicistat nedsætter den estimerede kreatininclearance på grund af hæmning af den tubulære sekretion af kreatinin. 
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Den intravenøse clearance af darunavir alene (150 mg) og ved tilstedeværelse af lavdosis (100 mg) ritonavir var henholdsvis 32,8 l/t og 5,9 l/t. 
The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose (100 mg) ritonavir was 32.8 l/h and 5.9 l/h, respectively.
Det vides ikke, om emtricitabin eller tenofovir kan fjernes med peritonealdialyse. 
It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.
ANTIMYKOTIKA Clotrimazol Fluconazol Itraconazol 
ANTIFUNGALS Clotrimazole Fluconazole Itraconazole
En potentiel risiko for nefrotoksicitet som følge af kronisk eksponering over for lave koncentrationer af tenofovir på grund af dosering af tenofoviralafenamid kan ikke udelukkes (se pkt. 
A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).
Co-administration af Symtuza med lægemidler, der primært metaboliseres af CYP3A, kan forårsage øget systemisk eksponering for sådanne lægemidler, hvilket kan øge eller forlænge både den terapeutiske virkning og bivirkninger. 
Co-administration of Symtuza and medicinal products primarily metabolised by CYP3A may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Co-administration af emtricitabin med lægemidler, der elimineres ved aktiv tubulær sekretion, kan øge koncentrationerne af emtricitabin og/eller det samtidigt administrerede lægemiddel. 
Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.
Lipidparameter Middelværdi ved baseline 
Lipid Parameter Baseline Median
Rosuvastatin (10 mg en gang dagligt): rosuvastatin AUC ↑ 93 % rosuvastatin Cmax ↑ 277 % rosuvastatin Cmin ND 
Rosuvastatin (10 mg once daily): rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin ND
Symtuza bør ikke initieres hos patienter med eGFRCG< 30 ml/min, eftersom der ikke findes nogen data vedrørende brugen af Symtuza hos denne population (se pkt. 
Symtuza should not be initiated in patients with eGFRCG < 30 mL/min, as there are no data available regarding the use of Symtuza in this population (see sections 5.1 and 5.2).
Baseline-CD4+-celletal <200 celler/mm ≥200 celler/mm 
Baseline CD4+ cell count < 200 cells/mm ≥ 200 cells/mm
Dette er mere sandsynligt ved langvarig hiv-behandling, alvorlig svækkelse af immunforsvaret, ved overvægt eller brug af alkohol eller lægemidler, der kaldes kortikosteroider (binyrebarkhormoner). 
This may be more likely with long-term HIV treatment, more severe damage to the immune system, being overweight, or the use of alcohol or medicines called corticosteroids.
Amiodaron Dronedaron Ivabradin Kinidin Ranolazin 
Amiodarone Dronedarone Ivabradine Quinidine Ranolazine
Forsøgsdeltagere med PDVF, n (%) 
Subjects with PDVF, n (%)
Fem forsøgsdeltagere forlod studiet af virkningsrelaterede årsager i henhold til investigators vurdering (lægens beslutning), hvoraf 3 havde sidste hiv-1 RNA under behandlingen < 50 kopier/ml. 
Five subjects were discontinued from the study due to efficacy related reasons per investigator's assessment (physician decision), of which 3 had last on treatment HIV-1 RNA <50 copies/mL.
Du kan stadig smitte andre med hiv, selvom du tager dette lægemiddel, men risikoen reduceres med effektiv antiretroviral terapi (medicin mod retrovirus, f.eks. hiv). 
You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
Brug af anden medicin sammen med Symtuza Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Other medicines and Symtuza Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Kontakt lægen, før du tager Symtuza. 
Talk to your doctor before taking Symtuza.
Brugen af Symtuza hos ART-naive unge patienter i alderen 12 år til < 18 år, og som vejer mindst 40 kg, understøttes af to studier af hiv-1-inficerede pædiatriske patienter (TMC114-C230 og GS-US-292-0106). 
The use of Symtuza in ART-naïve adolescent patients from the age of 12 years to < 18 years, and weighing at least 40 kg is supported by two trials in HIV-1 infected paediatric patients (TMC114-C230 and GS-US-292-0106).
Det emtricitabin-resistente virus med M184M/IV/-mutation var krydsresistent over for lamivudin, men bevarede følsomheden over for abacavir, stavudin, tenofovir og zidovudin. 
The emtricitabine-resistant virus with the M184M/I/V mutation was cross-resistant to lamivudine, but retained sensitivity to abacavir, stavudine, tenofovir, and zidovudine.
MALARIAMIDLER Artemether/lumefantrin 
ANTIMALARIALS Artemether/Lumefantrine
Fortæl det til din læge, hvis du tager: - Bosentan (til behandling af for højt blodtryk i lungekredsløbet) - Dexamethason (injektion) (kortikosteroid) - Boceprevir (til behandling af hepatitis C-infektion) - Rifapentin, rifabutin (til behandling af bakterieinfektioner) - Oxcarbazepin (til forebyggelse af krampeanfald). 
Tell your doctor if you take: - Bosentan (to treat high blood pressure in the pulmonary circulation) - Dexamethasone (injection) (corticosteroid) - Boceprevir (to treat hepatitis C virus infection) - Rifapentine, rifabutin (to treat bacterial infections) - Oxcarbazepine (to prevent seizures).
Sildenafil anvendes også til andre formål. 
There are other uses for sildenafil.
Atorvastatin (10 mg en gang dagligt): atorvastatin AUC ↑ 290 % atorvastatin Cmax ↑ 319 % atorvastatin Cmin ND 
Atorvastatin (10 mg once daily): atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin ND
Symtuzas sikkerhed og virkning hos patienter med samtidig hiv-1- og hepatitis C-virusinfektion (HCV) er ikke blevet klarlagt. 
The safety and efficacy of Symtuza in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
• Fjern det løse låg. 
• Remove the unscrewed cap.
I et flerdosisstudie med darunavir/ritonavir (600/100 mg) to gange dagligt blev det påvist, at den totale plasmakoncentration af darunavir hos forsøgspersoner med let (Child-Pugh klasse A, N=8) og moderat (Child-Pugh klasse B, N=8) nedsat leverfunktion var sammenlignelige med dem, der sås hos raske forsøgspersoner. 
In a multiple dose trial with darunavir/ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, N = 8) and moderate (Child-Pugh Class B, N = 8) hepatic impairment were comparable with those in healthy subjects.
Den gennemsnitlige systemisk emtricitabineksponering var højere hos patienter med svært nedsat nyrefunktion (eGFRCG <30 ml/min) (33,7-μg•t/ml) end hos personer med normal nyrefunktion (11,8 μg•t/ml). 
Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (eGFRCG < 30 mL/min) (33.7 mcg•h/mL) than in subjects with normal renal function (11.8 mcg•h/mL).
Ingen virologiske data 
No virologic data
Der findes ingen specifik antidot mod Symtuza. 
There is no specific antidote for overdose with Symtuza.
Der foreligger rapporter om mitokondriel dysfunktion hos hiv-negative spædbørn, som har været eksponeret for nukleosidanaloger in utero og/eller efter fødslen. 
There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues.
Formålet med lægemidlet 
Purpose of the medicine
Når Symtuza co-administreres med et lægemiddel, som indeholder drospirenon, anbefales klinisk monitorering på grund af risikoen for hyperkaliæmi. 
When Symtuza is coadministered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia.
Cobicistats hæmning af CYP3A-medieret metabolisme øger den systemiske eksponering over for CYP3A-substrater såsom darunavir, hvor biotilgængeligheden er begrænset og halveringstiden forkortet på grund af den CYP3A-afhængige metabolisme. 
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
Co-administration af cobicistat med lægemidler, der er substrater for disse transportører, kan medføre øgede plasmakoncentrationer af de samtidigt administrerede lægemidler. 
Co-administration of cobicistat with medicinal products that are substrates of these transporters can result in increased plasma concentrations of the co-administered medicinal products.
- Budesonid, fluticason (til behandling af astma). 
- Budesonide, fluticasone (to control asthma).
Tretten procent af dosis blev genfundet i urinen som tre formodede metabolitter. 
Thirteen percent of the dose was recovered in the urine as three putative metabolites.
DIREKTE VIRKENDE ANTIVIRALE MIDLER MOD HEPATITIS C (HCV) NS3-4A-hæmmere 
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS NS3-4A inhibitors
Ca. 95 % af darunavir bindes til plasmaprotein. 
Darunavir is approximately 95% bound to plasma protein.
Tag altid Symtuza nøjagtigt efter lægens eller apotekspersonalets anvisning. 
Always take Symtuza exactly as your doctor or pharmacist has told you.
Kombinationen kan medføre øget risiko for kardiovaskulære bivirkninger med salmeterol, herunder QT-forlængelse, palpitationer og sinustakykardi. 
The combination may result in increased risk of cardiovascular adverse events with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Ved uge 96 var middelændringen i eGFRCG -5,2 ml/min med D/C/F/TAF. 
At Week 96, the median change in eGFRCG was -5.2 mL/min with D/C/F/TAF.
Symtuza kan øge risikoen for blødning. 
Symtuza might increase the risk of bleeding.
Eksponeringen for darunavir og cobicistat administreret som Symtuza var henholdsvis 30-45 % og 16-29 % lavere i fastende sammenlignet med ikke-fastende tilstand. 
The exposure to darunavir and cobicistat administered as the Symtuza was 30-45% lower and 16-29% lower, respectively, in fasted compared to fed condition.
Efter intravenøs administration var fordelingsvolumen for darunavir administreret alene 88,1 ± 59,0 l (gennemsnit ± SD) og steg til 131 ± 49,9 l (gennemsnit ± SD) ved kombination med 100 mg ritonavir to gange dagligt. 
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 L (mean ± SD) and increased to 131 ± 49.9 L (mean ± SD) in the presence of 100 mg twice-daily ritonavir.
Symtuza kan co-administreres med H2-receptorantagonister uden dosisjusteringer. 
Symtuza can be co-administered with H2-receptor antagonists without dose adjustments.
Der er øget risiko for sildenafil-relaterede bivirkninger (herunder synsforstyrrelser, hypotension, forlænget erektion og synkope). 
There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope).
Relevante eksempler omfatter cytomegalovirus retinitis, generaliserede og/eller fokale mykobakterielle infektioner og pneumoni forårsaget af Pneumocystis jirovecii (tidligere kendt som Pneumocystis carinii). 
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii
Justering af methadondosis forventes ikke at være nødvendig, når co-administration med Symtuza påbegyndes. 
No adjustment of methadone dosage is expected when initiating co-administration with Symtuza.
Symtuza er et lægemiddel, der anvendes til behandling af hiv-1-infektion (humant immundefekt virus 1). 
Symtuza is an antiretroviral medicine used to treat infection with human immunodeficiency virus 1 (HIV-1).
Baseret på denne begrænsede erfaring forekommer sikkerhedsprofilen for emtricitabin/tenofoviralafenamid hos patienter co-inficeret med hiv/HBV at svare til den, der gælder for patienter, der kun er inficeret med hiv-1 (se pkt. 
Based on this limited experience, the safety profile of emtricitabine/tenofovir alafenamide in patients with HIV/HBV co-infection appears to be similar to that in patients with HIV-1 monoinfection (see section 4.4).
Hos nogle patienter med fremskreden leversygdom eller skrumpelever (cirrose) kan en afbrydelse af behandlingen medføre en forværring af hepatitis, der kan være livstruende. 
In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
Emtricitabins binding in vitro til humane plasmaproteiner var < 4 % og uafhængig af koncentrationen i intervallet 0,02-200 μg/ml. 
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 mcg/mL.
Se afsnittet 'Brug af anden medicin sammen med Symtuza'. 
Please see section ‘Other medicines and Symtuza'.